Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Common Equity (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Common Equity data on record, last reported at -$82.3 million in Q3 2025.

  • For Q3 2025, Common Equity fell 252.09% year-over-year to -$82.3 million; the TTM value through Sep 2025 reached -$82.3 million, down 252.09%, while the annual FY2024 figure was $29.5 million, 53.02% down from the prior year.
  • Common Equity reached -$82.3 million in Q3 2025 per GOSS's latest filing, down from -$46.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $104.6 million in Q3 2023 and bottomed at -$82.3 million in Q3 2025.
  • Average Common Equity over 4 years is $14.4 million, with a median of $26.7 million recorded in 2024.
  • The widest YoY moves for Common Equity: up 419.74% in 2023, down 281.51% in 2023.
  • A 4-year view of Common Equity shows it stood at $12.1 million in 2022, then surged by 419.74% to $62.8 million in 2023, then plummeted by 53.02% to $29.5 million in 2024, then crashed by 379.17% to -$82.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$82.3 million in Q3 2025, -$46.1 million in Q2 2025, and -$6.2 million in Q1 2025.